Skip to main content

Table 3 HPV prevalence at three mucosal sites (cervical, anal and oro-pharyngeal) stratified by genotype and known risk.

From: High prevalence of HPV in non-cervical sites of women with abnormal cervical cytology

  

LG patient samples (n = 129)

HG patient samples (n = 164)

  

Cervical (n = 44)

Anal (n = 41)

Oro-pharyngeal (n = 44)

Cervical (n = 56)

Anal (n = 52)

Oro-pharyngeal (n = 56)

 

16 (p = 0.41)

20 (45.5%)

24 (58.5%)

22 (50.0%)

33 (58.9%)

28 (53.8%)

31 (55.4%)

 

31 (p = 0.49)

10 (22.7%)

10 (24.4%)

13 (29.5%)

14 (25.0%)

10 (19.2%)

12 (21.4%)

High-risk (HR) & probable HR (PHR)

33 (p = 0.55)

8 (18.2%)

9 (22.0%)

10 (22.7%)

9 (16.1%)

6 (11.5%)

14 (25.0%)

 

53 (p = 0.083)

6 (13.6%)

10 (24.4%)

5 (11.4%)

5 (8.9%)

12 (23.1%)

3 (5.4%)

 

59 (p = 0.26)

6 (13.6%)

9 (22.0%)

9 (20.5%)

3 (5.4%)

7 (13.5%)

6 (10.7%)

 

45 (p = 0.40)

7 (15.9%)

11 (26.8%)

7 (15.9%)

6 (10.7%)

4 (7.7%)

4 (7.1%)

 

56 (p = 0.0004)

5 (11.4%)

7* (17.1%)

7# (15.9%)

2 (3.6%)

1 (1.9%)

2 (3.6%)

 

18 (p = 0.068)

1 (2.3%)

2 (4.9%)

2 (4.5%)

6 (10.7%)

5 (9.6%)

5 (8.9%)

 

66 (p = 0.0059)

3 (6.8%)

5 (12.2%)

4 (9.1%)

1 (1.8%)

1 (1.9%)

1 (1.8%)

 

Othersa

22

23

17

31

19

23

Low-risk (LR) b

18

16

10

12

15

8

Undetermined-risk (UDR) c

10

10

8

7

9

3

Total

116

136

114

129

117

112

  1. *#prevalence of HPV56 was significantly higher in anal (p = 0.0198) and oro-pharyngeal (p = 0.0406) samples from LG patients (Fisher's exact test, two-tailed). Only the 9 most frequent HR-HPV and PHR-HPV subtypes have been included in the table for clarity. acumulative occurrences of the remaining 12 HR-HPV & probable HR-HPV subtypes (26, 35, 39, 51, 52, 58, 68, 69, 70, 73, 82 and IS39). bcumulative occurrences of 9 LR-HPV subtypes (6, 11, 40, 42, 54, 61, 72, 81 and CP6108). ccumulative occurrences of 7 UDR-HPV subtypes (55, 62, 64, 67, 71, 83 and 84).